Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Jan;65(1):33–36. doi: 10.1038/bjc.1992.6

Effects on tumour microcirculation in mice of misonidazole and tumour necrosis factor plus hyperthermia.

S Fujimoto 1, K Kobayashi 1, M Takahashi 1, C Konno 1, M Kokubun 1, M Ohta 1, R D Shrestha 1, S Kiuchi 1
PMCID: PMC1977348  PMID: 1733439

Abstract

We examined the effects of misonidazole (MISO) and recombinant human tumour necrosis factor (rh-TNF) on tumour blood flow in mice given hyperthermic treatments. MISO (500 mg kg-1) or rh-TNF (6 x 10(4) unit kg-1) was administered intraperitoneally (i.p.) prior to hyperthermia to nude mice bearing a xenoplanted human gastric cancer and tumour blood flow was measured by a hydrogen diffusion method based on polarographic determinations. MISO plus hyperthermia produced a temperature-dependent decrease in blood flow and, at 43.5 degrees C, the flow decreased to 15-30% of control and remained low for up to 24 h. Blood flow following rh-TNF plus hyperthermia was less than that at the same temperatures following MISO plus hyperthermia, and, at 43.5 degrees C, the flow decreased to 10-20% of control and remained low for up to 48 h. Tumour growth delay was closely related to the duration of the decrease in blood flow. Thus, the profound decrease in tumour blood flow following hyperthermia plus MISO or rh-TNF and the consequential tumour regression may well be of potential clinical significance.

Full text

PDF
33

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AUKLAND K., BOWER B. F., BERLINER R. W. MEASUREMENT OF LOCAL BLOOD FLOW WITH HYDROGEN GAS. Circ Res. 1964 Feb;14:164–187. doi: 10.1161/01.res.14.2.164. [DOI] [PubMed] [Google Scholar]
  2. Adams G. E., Flockhart I. R., Smithen C. E., Stratford I. J., Wardman P., Watts M. E. Electron-affinic sensitization. VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. Radiat Res. 1976 Jul;67(1):9–20. [PubMed] [Google Scholar]
  3. Bleehen N. M., Honess D. J., Morgan J. E. Interaction of hyperthermia and the hypoxic cell sensitizer Ro-07-0582 on the EMT6 mouse tumour. Br J Cancer. 1977 Mar;35(3):299–306. doi: 10.1038/bjc.1977.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Creasey A. A., Doyle L. V., Reynolds M. T., Jung T., Lin L. S., Vitt C. R. Biological effects of recombinant human tumor necrosis factor and its novel muteins on tumor and normal cell lines. Cancer Res. 1987 Jan 1;47(1):145–149. [PubMed] [Google Scholar]
  5. Denekamp J., Hill S. A., Hobson B. Vascular occlusion and tumour cell death. Eur J Cancer Clin Oncol. 1983 Feb;19(2):271–275. doi: 10.1016/0277-5379(83)90426-1. [DOI] [PubMed] [Google Scholar]
  6. Eddy H. A. Alterations in tumor microvasculature during hyperthermia. Radiology. 1980 Nov;137(2):515–521. doi: 10.1148/radiology.137.2.7433685. [DOI] [PubMed] [Google Scholar]
  7. Fujimoto S., Konno C., Kobayashi K., Kokubun M., Shrestha R. D., Kiuchi S., Takahashi M., Ohta M., Okui K. Augmented antitumour effects of combined treatment with hyperthermia and tumour necrosis factor on human gastric cancer xenotransplanted into nude mice. Int J Hyperthermia. 1991 May-Jun;7(3):511–518. doi: 10.3109/02656739109005015. [DOI] [PubMed] [Google Scholar]
  8. Gray A. J., Dische S., Adams G. E., Flockhart I. R., Foster J. L. Clinical testing of the radiosensitiser Ro-07-0582. I. Dose tolerance, serum and tumour concentrations. Clin Radiol. 1976 Apr;27(2):151–157. doi: 10.1016/s0009-9260(76)80137-7. [DOI] [PubMed] [Google Scholar]
  9. Hahn G. M. Potential for therapy of drugs and hyperthermia. Cancer Res. 1979 Jun;39(6 Pt 2):2264–2268. [PubMed] [Google Scholar]
  10. Hall E. J., Astor M., Geard C., Biaglow J. Cytotoxicity of Ro-07-0582; enhancement by hyperthermia and protection by cysteamine. Br J Cancer. 1977 Jun;35(6):809–815. doi: 10.1038/bjc.1977.122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Honess D. J., Morgan J. E., Bleehen N. M. The hyperthermic potentiation of the cytotoxic effect of misonidazole on the EMT6 mouse tumour: relevance of in vitro measurement of in vivo effect. Br J Cancer Suppl. 1978 Jun;3:173–177. [PMC free article] [PubMed] [Google Scholar]
  12. Kun L. E., Ho K. C., Moulder J. E. Fatal misonidazole-induced encephalopathy: an RTOG case report. Cancer. 1982 Feb 1;49(3):423–426. doi: 10.1002/1097-0142(19820201)49:3<423::aid-cncr2820490305>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  13. Matthews N., Watkins J. F. Tumour-necrosis factor from the rabbit. I. Mode of action, specificity and physicochemical properties. Br J Cancer. 1978 Aug;38(2):302–309. doi: 10.1038/bjc.1978.202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Murray J. C., Randhawa V. S. Misonidazole reduces blood flow in two experimental murine tumours. Br J Cancer. 1988 Aug;58(2):128–132. doi: 10.1038/bjc.1988.178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Nawroth P. P., Stern D. M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 1986 Mar 1;163(3):740–745. doi: 10.1084/jem.163.3.740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Overgaard J. Effect of hyperthermia on malignant cells in vivo. A review and a hypothesis. Cancer. 1977 Jun;39(6):2637–2646. doi: 10.1002/1097-0142(197706)39:6<2637::aid-cncr2820390650>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  17. Overgaard J. Effect of misonidazole and hyperthermia on the radiosensitivity of a C3H mouse mammary carcinoma and its surrounding normal tissue. Br J Cancer. 1980 Jan;41(1):10–21. doi: 10.1038/bjc.1980.2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Saunders M. E., Dische S., Anderson P., Flockhart I. R. The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum. Br J Cancer Suppl. 1978 Jun;3:268–270. [PMC free article] [PubMed] [Google Scholar]
  19. Shine N., Palladino M. A., Jr, Patton J. S., Deisseroth A., Karczmar G. S., Matson G. B., Weiner M. W. Early metabolic response to tumor necrosis factor in mouse sarcoma: a phosphorus-31 nuclear magnetic resonance study. Cancer Res. 1989 Apr 15;49(8):2123–2127. [PubMed] [Google Scholar]
  20. Stratford I. J., Adams G. E. Effect of hyperthermia on differential cytotoxicity of a hypoxic cell radiosensitizer, Ro-07-0582, on mammalian cells in vitro. Br J Cancer. 1977 Mar;35(3):307–313. doi: 10.1038/bjc.1977.44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Sugarman B. J., Aggarwal B. B., Hass P. E., Figari I. S., Palladino M. A., Jr, Shepard H. M. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science. 1985 Nov 22;230(4728):943–945. doi: 10.1126/science.3933111. [DOI] [PubMed] [Google Scholar]
  22. Taguchi T. [A phase I study of recombinant human tumor necrosis factor (rHu-TNF: PT-050). The PT-050 Study Group]. Gan To Kagaku Ryoho. 1986 Dec;13(12):3491–3497. [PubMed] [Google Scholar]
  23. Watanabe N., Niitsu Y., Umeno H., Kuriyama H., Neda H., Yamauchi N., Maeda M., Urushizaki I. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res. 1988 Apr 15;48(8):2179–2183. [PubMed] [Google Scholar]
  24. Watanabe N., Niitsu Y., Umeno H., Sone H., Neda H., Yamauchi N., Maeda M., Urushizaki I. Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. Cancer Res. 1988 Feb 1;48(3):650–653. [PubMed] [Google Scholar]
  25. Yamazaki S., Onishi E., Enami K., Natori K., Kohase M., Sakamoto H., Tanouchi M., Hayashi H. Proposal of standardized methods and reference for assaying recombinant human tumor necrosis factor. Jpn J Med Sci Biol. 1986 Jun;39(3):105–118. doi: 10.7883/yoken1952.39.105. [DOI] [PubMed] [Google Scholar]
  26. ZIERLER K. L. EQUATIONS FOR MEASURING BLOOD FLOW BY EXTERNAL MONITORING OF RADIOISOTOPES. Circ Res. 1965 Apr;16:309–321. doi: 10.1161/01.res.16.4.309. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES